Switzerland-based Addex Therapeutics Ltd has raised $4.2 million in equity finance in order to carry forward clinical and pre-clinical programmes directed at neurological disorders. The financing was arranged through Armistice Master Fund Ltd, an institutional investor, and was announced on 26 July. It makes a significant contribution to the company’s cash position which was CHF 8.8 million ($9.24 million) on 30 June, by extending cash well into 2023.
Pharming Group NV is to get an accelerated review from the European Medicines Agency for leniolisib, its candidate treatment for a rare primary immunodeficiency known as activated phosphoinositide 3-kinase delta syndrome (APDS). A marketing authorisation application is expected to be submitted to the EMA in October, the company announced on 1 August.
Sanofi SA generated sales of €10.1 billion in the second quarter with Dupixent, jointly developed with Regeneron Pharmaceuticals Inc, making the single biggest contribution to turnover. Sales for the company as a whole increased by 15.7%, while sales for Dupixent, an anti-inflammatory drug, rose by 58% to €1.96 billion.
AstraZeneca Plc reported a 31% increase in total revenue to $10.8 billion for the second quarter, driven by its cardiovascular and oncology medicines as well as income from Alexion Pharmaceuticals, a developer of drugs for rare diseases which it acquired in July 2021. The second quarter revenue figure includes three drugs with more than $1 billion in sales: Tagrisso for lung cancer; Farxiga, for diabetes, heart failure and kidney disease; and Alexion’s Soliris for myasthenia gravis and three other rare diseases.
GlaxoSmithKline Plc has revised upward its sales and adjusted operating profit guidance for 2022 – its first financial forecast since the demerger on 18 July of Haleon, its consumer products business. The new GSK is expected to produce sales growth of between 6%-8% this year, up from the previously forecast 5%-7%. Adjusted operating profit is expected to grow by between 13% to 15%, compared with a previous range of 12% to 14%.
The Roche Group is forecasting stable to modest sales growth this year as it transitions to new leadership and continues to launch more products to offset the impact of biosimilar competition for its legacy medicines. Severin Schwan, chief executive since 2008, will step down from his post on 14 March 2023 and be succeeded by Thomas Schinecker, currently CEO of the diagnostics division. Dr Schwan is to be nominated as chairman of the company’s board of directors.
AbbVie Inc of the US has formed an alliance with the Belgian company iSTAR Medical SA to further develop and commercialise a surgical device for treating patients with glaucoma. Glaucoma is a progressive disease estimated to affect more than 100 million people globally of which primary open-angle glaucoma is the most common form. The iSTAR device is designed to enhance natural fluid outflow from the eye, reducing intraocular pressure and the need for medication.
Novartis saw its operating profit decline in the second quarter but sales of core products such as Entresto for heart failure and Kisqali for breast cancer delivered double-digit sales growth. Turnover for the group as a whole was $12.8 billion, down by 1% from a year earlier. Measured at constant exchange rates, group sales increased by 5%.
Oxford Science Enterprises (OSE), an independent investor in science generated at the University of Oxford, has raised £250 million from a group of new and existing investors enabling it to extend its financial support to start-up companies across the life sciences, healthcare technology and deep technology sector. In addition to providing seed funding, OSE supports later-stage funding rounds for more mature companies in its portfolio.
Enterome has entered into a new partnership to support development of its pipeline of microbiome-based therapeutics – this time with Nestlé Health Science. The deal will deliver €40 million upfront in cash and equity from Nestlé, enabling Enterome to bring its lead immune disease product into the clinic. This product, EB1010, is an inducer of the interleukin-10 cytokine. IL-10 has anti-inflammatory properties that play a central role in maintaining normal tissue homeostasis.